* PAVmed Inc PAVM.OQ PAVM.O is expected to show a rise
in
quarterly revenue when it reports results on May 13 for the
period ending March 31 2024
* The New York City-based company is expected to report a
136.0% increase in revenue to $1.053 million from $446 thousand
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for PAVmed Inc is for a loss
of
$1.67 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for PAVmed Inc
is
$6.50, above its last closing price of $2.25.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -1.47 -1.89 -1.81 Beat 4.2
Sep. 30 0001 -2.04 -2.05 -2.40 Missed -17.1
Jan. 1 0001 -2.84 -2.85 -2.10 Beat 26.3
Mar. 31 2023 -3.11 -3.10 -2.85 Beat 8.1
Dec. -3.84 -3.80 -3.45 Beat 9.2
31 2022
Sep. 30 2022 -3.98 -3.97 -4.35 Missed -9.4
Jan. 1 0001 -3.45 -3.45 -4.35 Missed -26.1
Mar. 31 2022 -2.88 -2.92 -3.00 Missed -2.6
This summary was machine generated May 10 at 20:09 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)